TNX-601 CR*: a Once-Daily Formulation of Tianeptine in Development for the Treatment of Major Depressive Disorder

Presented at CNS Summit 2021 in Boston, Mass., November 7-10, 2021.

Gregory M Sullivan¹, David T Hsu¹, Ashild Peters¹, Perry Peters¹, Siobhan Fogarty¹, Regina Kiu¹, Bernd Meibohm², Seth Lederman¹

¹Tonix Pharmaceuticals Inc, ²University of Tennessee Health Sciences Center

*TNX-601 CR is an investigational new drug and has not been approved for any indication.

TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial

Presented by Greg Sullivan, M.D. and CMO of Tonix, at the American College of Rheumatology (ACR) Convergence 2021 on November 6, 2021

Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Trial

Presented at the American Society of Clinical Psychopharmacology (ASCP) 2021 Annual Meeting Virtual Conference, June 01-04, 2021

Gregory Sullivan¹, Mary Kelley¹, Annabelle Iserson¹, Perry Peters¹, Ashild Peters¹, Candace Flint¹, Judy Gendreau², Herb Harris¹, Ben Vaughn³, and Seth Lederman¹

¹Tonix Pharmaceuticals, Inc., New York, NY ²Gendreau Consulting LLC, Poway, CA ³Rho, Inc, Chapel Hill, NC

Effect of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) on PTSD Sleep-Dependent Emotional Memory Processing: Retrospective Analysis of Phase 2 and 3 Trial Results in Military-Related and Civilian PTSD

Presented at the American Society of Clinical Psychopharmacology (ASCP) 2021 Annual Meeting Virtual Conference, June 01-04, 2021

Megan Parmenter¹, Annabelle Iserson², Jean Engels³, Bernard Gorman¹, Seth Lederman², and Gregory Sullivan²

¹Adelphi University, ²Tonix Pharmaceuticals, Inc. ³Engels Statistical Consulting LLC

Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)

Presented at the American Academy of Neurology’s Sports Concussion Conference held virtually July 31 – August 1, 2020

Shashidhar H Kori, David Yeomans, Michael Klukinov

Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer

Presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020

Woosook Kim, Na Fu, Phaneendra Duddempudi, Zinaida Dubeykovskaya, Steven Almo, Chandan Guha, Seth Lederman, Timothy Wang

Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox*

Presented at the American Society of Microbiology (ASM) BioThreats Conference in Arlington, VA on January 29, 2020 Poster Session #2 - 4:15 pm.

Ryan Noyce, Landon Westfall, Siobhan Fogarty, Karen Gilbert, Onesmo Mpanju, Helen Stillwell, Jose Esparza, Fusataka Koide, David Evans, and Seth Lederman

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome

Presented by Dr. Gregory Sullivan at the American College of Rheumatology in Atlanta, GA on November 10, 2019

Gregory Sullivan, R. Michael Gendreau, Judith Gendreau, Ashild Peters, Perry Peters, and Seth Lederman

Steady-State Pharmacokinetic Properties of a Sublingual Formulation of Cyclobenzaprine (CBP) HCl (TNX-102 SL*): Comparison to Simulations of Oral Immediate Release CBP

Presented at the American Society of Clinical Psychopharmacology in Scottsdale, AZ on May 29, 2019 Poster Session I – Poster ID W29, 11:15 AM – 1 PM EDT, Palomino

Gregory Sullivan, Regina Kiu, Helen Stillwell, Bernd Meibohm, and Seth Lederman

Time Since Trauma in PTSD: Phase 3 Multi-Center, Double-Blind, Placebo-Controlled Trial of TNX-102 SL*,a Sublingual Formulation of Cyclobenzaprine, in Military-Related PTSD (Study TNX-CY-P301)

Presented at CNS Summit in Boca Raton, FL November 1-4, 2018; Poster 8A, Friday Nov. 2, 5:00-7:00 PM EDT, Reception and Poster Session, and abstract published in Innovations in Clinical Neuroscience, November-December 2018;15(11-12, suppl):S10.

Gregory Sullivan, MD, R Michael Gendreau, MD, PhD, Judy Gendreau, MD, Ashild Peters, RN, Perry Peters, Jean Engels, MS, Seth Lederman, MD